The Round Cell Liposarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Round Cell Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Round Cell Liposarcoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Round Cell Liposarcoma and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Round Cell Liposarcoma by nine companies/universities/institutes. The top development phase for Round Cell Liposarcoma is phase ii with five drugs in that stage. The Round Cell Liposarcoma pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Round Cell Liposarcoma pipeline products market are: Immutep, 3SBio and SOTIO Biotech.
The key targets in the Round Cell Liposarcoma pipeline products market include Cells Expressing Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Major Histocompatibility Complex (MHC) Class II.
The key mechanisms of action in the Round Cell Liposarcoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with two drugs in Phase II. The Round Cell Liposarcoma pipeline products include seven routes of administration with the top ROA being Intravenous and four key molecule types in the Round Cell Liposarcoma pipeline products market including Gene-Modified Cell Therapy, and Monoclonal Antibody.
Round Cell Liposarcoma overview
Round cell liposarcoma, also called myxoid or MRCLS, is one of several types of liposarcoma. Liposarcoma is a rare cancer that grows in the cells that store fat in the body. MRCLS tumors usually grow in the arms and legs. These tumors grow slowly, and they can spread to other parts of the body.
For a complete picture of Round Cell Liposarcoma’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
